The provision of key health technologies and products such as vaccines and antibiotics is insufficient in purely competitive and volume-based markets, requiring new revenue streams for sustainability. Recent developments in health innovation suggest that innovative collaborative mechanisms can be effective in addressing this issue. In the domains of vaccines and antibiotics, these approaches should incorporate shared research investment, long-term access planning, the provision of manufacturing infrastructure, supply chains, and financial returns. Collaborative approaches such as subscription models could be piloted at the regional level, while other models could be developed to delink innovation, manufacturing, and access from sales volume and revenue. Finally, blended finance instruments from the development field could encourage greater collaboration among established and emerging stakeholders in health innovation. These stakeholders should work together to create, test, access, and implement more collaborative approaches to health innovation to share upfront investments, mitigate risks of failure, and accelerate market access.
Collaborative mechanisms for sustainable health innovation
The case of vaccines and antibiotics
Policy paper
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
21 May 202645 Pages
-
Policy paper
Trends and priorities, 2019‑2023
20 May 202648 Pages -
4 December 202563 Pages
-
1 December 202537 Pages
-
Policy paper
A case study within the OECD’s Global Green Iron project
22 October 202564 Pages
Related publications
-
21 May 202645 Pages
-
29 April 202643 Pages
-
14 April 202674 Pages
-
23 November 202510 Pages
-
20 October 202555 Pages